share_log

Vivos Therapeutics | 10-K/A: Annual report (Amendment)

Vivos Therapeutics | 10-K/A: Annual report (Amendment)

Vivos Therapeutics | 10-K/A:年度報表(修正版)
美股sec公告 ·  07/30 06:06
Moomoo AI 已提取核心訊息
Vivos Therapeutics, a medical technology company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company experienced a net loss of $13.6 million, a decrease from the previous year's net loss of $23.8 million. Total revenue for the year was $13.8 million, down from $16 million in the prior year. Product revenue, primarily from appliance sales to VIPs, contributed $6.3 million, while service revenue accounted for $7.5 million. The company's operating loss was $17.3 million, an improvement from the $25 million operating loss reported in the previous year. Vivos Therapeutics also highlighted its business developments, including the acquisition of patents and intellectual property from Advanced Facialdontics, LLC, and the issuance of common stock and warrants in private placements. Looking ahead, the company plans to continue its strategic initiatives and investment plans to drive growth and achieve profitability.
Vivos Therapeutics, a medical technology company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company experienced a net loss of $13.6 million, a decrease from the previous year's net loss of $23.8 million. Total revenue for the year was $13.8 million, down from $16 million in the prior year. Product revenue, primarily from appliance sales to VIPs, contributed $6.3 million, while service revenue accounted for $7.5 million. The company's operating loss was $17.3 million, an improvement from the $25 million operating loss reported in the previous year. Vivos Therapeutics also highlighted its business developments, including the acquisition of patents and intellectual property from Advanced Facialdontics, LLC, and the issuance of common stock and warrants in private placements. Looking ahead, the company plans to continue its strategic initiatives and investment plans to drive growth and achieve profitability.
醫療科技公司vivos therapeutics報告了截至2023年12月31日的財政年度的年度財務業績。該公司的淨虧損爲1360萬美元,較上年的2380萬美元的淨虧損有所減少。該年度的總營業收入爲1380萬美元,低於上一年的1600萬美元。主要來自會員的設備銷售的產品收入貢獻了630萬美元,而服務收入佔了750萬美元。該公司的營業虧損爲1730萬美元,較上年的2500萬美元的營業虧損有所改善。vivos therapeutics還強調了其業務發展,包括從愛文思控股有限責任公司收購專利和知識產權以及在私人配售中發行普通股和認股權證。展望未來,該公司計劃繼續其戰略舉措和投資計劃,推動增長並實現盈利能力。
醫療科技公司vivos therapeutics報告了截至2023年12月31日的財政年度的年度財務業績。該公司的淨虧損爲1360萬美元,較上年的2380萬美元的淨虧損有所減少。該年度的總營業收入爲1380萬美元,低於上一年的1600萬美元。主要來自會員的設備銷售的產品收入貢獻了630萬美元,而服務收入佔了750萬美元。該公司的營業虧損爲1730萬美元,較上年的2500萬美元的營業虧損有所改善。vivos therapeutics還強調了其業務發展,包括從愛文思控股有限責任公司收購專利和知識產權以及在私人配售中發行普通股和認股權證。展望未來,該公司計劃繼續其戰略舉措和投資計劃,推動增長並實現盈利能力。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息